This study has demonstrated that mesna co-administration decreases TNF-α, TNFR1 and TNFR2 levels after Dox-containing chemotherapy as compared to receiving Dox-containing chemotherapy alone, indicating a potential role for mesna in mediating toxicities resulting from TNF-α signaling during cancer treatment. The gene discussed is TNFRSF1B; the disease is cancer.